AR072520A1 - Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico - Google Patents

Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico

Info

Publication number
AR072520A1
AR072520A1 ARP090102729A ARP090102729A AR072520A1 AR 072520 A1 AR072520 A1 AR 072520A1 AR P090102729 A ARP090102729 A AR P090102729A AR P090102729 A ARP090102729 A AR P090102729A AR 072520 A1 AR072520 A1 AR 072520A1
Authority
AR
Argentina
Prior art keywords
treatment
idrabiotaparinux
incidence
during
use according
Prior art date
Application number
ARP090102729A
Other languages
English (en)
Inventor
Roger Cariou
Louise Silvestre
Gerard Pillion
Paul Chew
Jean-Michel Destors
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08290704A external-priority patent/EP2145624A1/en
Priority claimed from EP09290216A external-priority patent/EP2233143A1/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR072520A1 publication Critical patent/AR072520A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere al uso de idrabiotaparinux para el tratamiento y la prevencion secundaria de patologías tromboticas, en el que el uso de idrabiotaparinux implica una disminucion en la incidencia de hemorragias, en particular hemorragias masivas, durante dicho tratamiento. Reivindicacion 3: El uso segun la reivindicacion 1 o la reivindicacion 2, en el que la patología trombotica es tromboembolismo venoso. Reivindicacion 4: El uso segun cualquiera de las reivindicaciones 1 a 3, en el que la patología trombotica es trombosis venosa profunda. Reivindicacion 5: El uso segun cualquiera de las reivindicaciones 1 a 4, en el que dicho medicamento es util para el tratamiento de tromboembolismo venoso y para la prevencion de sucesos tromboembolicos venosos posteriores. Reivindicacion 6: El uso segun cualquiera de las reivindicaciones 1 a 5, en el que la incidencia de hemorragias está disminuida en comparacion con un tratamiento bien mediante idraparinux o un antagonista de vitamina K.
ARP090102729A 2008-07-18 2009-07-17 Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico AR072520A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290704A EP2145624A1 (en) 2008-07-18 2008-07-18 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP09290216A EP2233143A1 (en) 2009-03-24 2009-03-24 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment

Publications (1)

Publication Number Publication Date
AR072520A1 true AR072520A1 (es) 2010-09-01

Family

ID=41203891

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102729A AR072520A1 (es) 2008-07-18 2009-07-17 Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico

Country Status (15)

Country Link
US (1) US20110245200A1 (es)
EP (1) EP2315593A1 (es)
JP (1) JP2011528345A (es)
KR (1) KR20110044747A (es)
CN (1) CN102149389A (es)
AR (1) AR072520A1 (es)
AU (1) AU2009272373A1 (es)
BR (1) BRPI0915947A2 (es)
CA (1) CA2730975A1 (es)
IL (1) IL210692A0 (es)
MX (1) MX2011000673A (es)
RU (1) RU2011106037A (es)
TW (1) TW201006479A (es)
UY (1) UY31995A (es)
WO (1) WO2010007530A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917552B (zh) * 2011-06-17 2017-03-29 卡博梅麦特斯公司 具有短半衰期和高活性的合成五糖

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
RU2434876C2 (ru) * 2005-10-10 2011-11-27 Н.В. Органон Антитромботические двойные ингибиторы, включающие биотиновую метку

Also Published As

Publication number Publication date
KR20110044747A (ko) 2011-04-29
RU2011106037A (ru) 2012-08-27
EP2315593A1 (en) 2011-05-04
BRPI0915947A2 (pt) 2019-04-09
UY31995A (es) 2010-02-26
MX2011000673A (es) 2011-04-04
JP2011528345A (ja) 2011-11-17
CN102149389A (zh) 2011-08-10
WO2010007530A1 (en) 2010-01-21
AU2009272373A1 (en) 2010-01-21
IL210692A0 (en) 2011-03-31
US20110245200A1 (en) 2011-10-06
TW201006479A (en) 2010-02-16
CA2730975A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
PH12020550768A1 (en) Compositions and methods of use of phorbol esters
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
WO2015038939A3 (en) Modulators of complement factor b
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
CL2012003125A1 (es) Metodo para eliminar microbios de las manos que comprende una composicion farmaceutica que comprende povidona yodada, una amida terciaria, aceite de coco, al menos un tensioactivo y agua; composicion farmaceutica.
BR112016002233A2 (pt) composições de adoçante
UY31789A1 (es) Composiciones de insulina de super rápida actuación
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
CL2012000976A1 (es) Composicion antitranspirante que comprende una base, un activo antiperspirante y por lo menos un antioxidante; y metodo para reducir o eliminar la coloracion amarilla en las prendas de vestir.
GB201215159D0 (en) Composition
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
BR112015023387A2 (pt) composições lipídicas de racecodotril
AR098888A1 (es) Composición para el cuidado oral
GB201105050D0 (en) Pharmaceutical agent
WO2010066346A3 (en) Composition for the prevention and treatment of viral infections
UY32408A (es) Macrolido anti-inflamatorio
WO2013060744A3 (en) 1, 2, 4 - oxadiazole derivatives as ethr inhibitors for use in the treatment tuberculosis
AR083380A1 (es) Mecanismo de establecimiento de dosis y metodo para utilizar el mismo
RU2013110517A (ru) Средство для профилактики или лечения неалкогольного стеатогепатита
AR072520A1 (es) Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombotico
AR083796A1 (es) Composicion sinergistica antimicrobiana de 1,2-benzisotiazolin-3-ona y tris(hidroximetil)nitrometano
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
EA201301197A1 (ru) Композиция энтакапона

Legal Events

Date Code Title Description
FA Abandonment or withdrawal